Personalis, Inc. PSNL stock is up in Tuesday’s premarket session after the company received Medicare coverage for its NeXT Personal molecular residual disease test for lung cancer surveillance. This ...

Recurring 410(b) failures are rarely random. When a plan consistently struggles with coverage testing, it’s not bad luck. It’s structural. Maybe the ownership group is highly compensated and aging ...

Personalis Inc. PSNL received a favorable reimbursement decision that could make its cancer test available to more patients — ...

TIME IS RUNNING OUT FOR CONGRESS TO APPROVE MEDICARE COVERAGE FOR A SIMPLE BLOOD TEST THAT CAN HELP DETECT CANCER IN EARLIER, MORE TREATABLE STAGES. ADVOCATES TONIGHT SAY WITHOUT MEDICARE COVERAGE, ...

Learn more Marks the first Medicare coverage decision for Veracyte’s whole-genome sequencing-based TrueMRD platform and launch of the first test SOUTH SAN FRANCISCO, Calif., May 15, 2026--(BUSINESS ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...